{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:09:00Z","timestamp":1759230540369},"reference-count":42,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2020,8,2]]},"DOI":"10.1080\/03007995.2020.1783220","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T23:28:56Z","timestamp":1592350136000},"page":"1393-1401","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["FDA approved vs. Pharmacy compounded 17-OHPC\u2014current issues for obstetricians to consider in reducing recurrent preterm birth"],"prefix":"10.1080","volume":"36","author":[{"given":"David L.","family":"Gandell","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Randell","sequence":"additional","affiliation":[{"name":"OBGYN Atlanta, Emory Saint Joseph\u2019s Hospital, Atlanta, GA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Gudeman","sequence":"additional","affiliation":[{"name":"AMAG Pharmaceuticals, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2016.03.011"},{"key":"CIT0002","unstructured":"March of Dimes. 2019. March of Dimes Report Card; [cited 2020 May 21]. Available from: https:\/\/www.marchofdimes.org\/mission\/reportcard.aspx."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70111-0"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035140"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002868"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.03.020"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(03)00494-6"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.41"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.06.034"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1215432"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1990.tb01740.x"},{"key":"CIT0012","unstructured":"Division of Bone, Reproductive, and Urologic Products. Office of New Drugs, Center for Drug Evaluation and Research. Food and Drug Administration. Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) Meeting October 29, 2019. FDA Briefing Document NDA 021945. Hydroxyprogesterone Caproate Injection (trade name Makena). October 2019; [cited 2020 Mar 27]. Available from: https:\/\/www.fda.gov\/media\/132003\/download."},{"key":"CIT0013","unstructured":"Division of Bone, Reproductive, and Urologic Products. Center for Drug Evaluation and Research. Medical Review: Application number 21945Orig1s000. February 2011; [cited 2020 Mar 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/021945Orig1s000MedR.pdf."},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.2165\/11640850-000000000-00000"},{"key":"CIT0015","unstructured":"United States Food and Drug Administration. FDA statement on Makena. March 30, 2011; [cited 2020 Mar 29]. Available from: https:\/\/wayback.archive-it.org\/7993\/20170113192840\/. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm249025.htm."},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2012.662511"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.07.003"},{"key":"CIT0018","unstructured":"American College of Obstetricians and Gynecologists. Society for Maternal-Fetal Medicine. Information update on 17a-hydroxyprogesterone caproate (17P) from the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. October 13, 2011."},{"key":"CIT0019","unstructured":"United States Food and Drug Administration. Questions and answers on updated FDA statement on compounded versions of hydroxyprogesterone caproate (the active ingredient in Makena). June 2012; [cited 2020 Mar 29]. Available from: https:\/\/wayback.archive-it.org\/7993\/20170113105722\/http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm310215.htm."},{"key":"CIT0020","unstructured":"United States Food and Drug Administration. FDA\u2019s human drug compounding progress report: Three years after enactment of the Drug Quality and Security Act. January 2017; [cited 2020 Mar 27]. Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fdas-human-drug-compounding-progress-report-three-years-after-enactment-drug-quality-and-security."},{"key":"CIT0021","unstructured":"Raymond N. US prosecutors seek 35 years in prison for meningitis outbreak exec. June 23, 2017; [cited 2020 Mar 27]. Available from: https:\/\/www.reuters.com\/article\/us-massachusetts-meningitis-idUSKBN19E1GR."},{"key":"CIT0022","volume-title":"(hydroxyprogesterone caproate injection) for intramuscular use [package insert]","author":"MAKENA\u00ae","year":"2018"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.10.020"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1604195"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3400227"},{"key":"CIT0026","unstructured":"Amag Pharmaceuticals, Inc. Amag Pharmaceuticals announces topline results from the PROLONG trial evaluating MAKENA\u00ae (hydroxyprogesterone caproate injection). March 8, 2019; [cited 2020 May 20]. Available from: https:\/\/www.amagpharma.com\/news\/amag-pharmaceuticals-announces-topline-results-from-the-prolong-trial-evaluating-makena-hydroxyprogesterone-caproate-injection\/."},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003115"},{"key":"CIT0028","unstructured":"Division of Bone, Reproductive, and Urologic Products. Office of New Drugs, Center for Drug Evaluation and Research. Food and Drug Administration. Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC). Transcript for the October 29, 2019 Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC). October 2019; [cited 2020 May 21]. Available from: https:\/\/www.fda.gov\/media\/136108\/download."},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1002\/uog.5158"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00350-0"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002390"},{"key":"CIT0032","unstructured":"United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Centers for Biologics Evaluation and Research (CBER). Center for Veterinary Medicine (CVM). Office of Regulatory Affairs (ORA). Guidance for industry. Quality systems approach to pharmaceutical current good manufacturing practice regulations. September 2006; [cited 2020 Mar 27]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations."},{"key":"CIT0033","unstructured":"United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Office of Compliance\/OUDLC. Guidance for industry. Compounding drug products that are essentially copies of approved drugs under section 503B of the Federal, Food, Drug, and Cosmetic Act. January 2018; [cited 2020 Apr 14]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/compounded-drug-products-are-essentially-copies-approved-drug-products-under-section-503b-federal."},{"key":"#cr-split#-CIT0034.1","unstructured":"The Pew Charitable Trusts. U.S. Illnesses and deaths associated with compounded or repackaged medications, 2001-19. March 2020"},{"key":"#cr-split#-CIT0034.2","unstructured":"[cited 2020 Apr 14]. Available from: https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/data-visualizations\/2020\/us-illnesses-and-deaths-associated-with-compounded-or-repackaged-medications-2001-19."},{"key":"CIT0035","unstructured":"United States Food and Drug Administration. Limited FDA Survey of Compounded Drug Products. 2001; [cited 2020 Mar 29]. Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/report-limited-fda-survey-compounded-drug-products."},{"key":"CIT0036","unstructured":"United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Centers for Biologics Evaluation and Research (CBER). Guidance for industry. Drug master files (draft guidance). October 2019; [cited 2020 Mar 29]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-master-files-guidance-industry."},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000749"},{"key":"CIT0038","unstructured":"American College of Obstetricians and Gynecologists. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Compounded bioidentical menopausal hormone therapy. Committee opinion number 532. August 2012; [cited 2020 Mar 29]. Available from: https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2012\/08\/compounded-bioidentical-menopausal-hormone-therapy."},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000921"},{"key":"CIT0040","unstructured":"American College of Obstetricians and Gynecologists. ACOG statement on 17P hydroxyprogestrone caproate. October 2019; [cited 2020 Mar 29]. Available from: https:\/\/www.acog.org\/news\/news-releases\/2019\/10\/acog-statement-on-17p-hydroxyprogesterone-caproate."},{"key":"CIT0041","unstructured":"Society for Maternal-Fetal Medicine Publications Committee. SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth. October 2019; [cited 2020 Mar 29]. Available from: https:\/\/els-jbs-prod-cdn.literatumonline.com\/pb\/assets\/raw\/Health%20Advance\/journals\/ymob\/SMFM_Statement_PROLONG-1572023839767.pdf."}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2020.1783220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T12:45:34Z","timestamp":1596026734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2020.1783220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,2]]}},"alternative-id":["10.1080\/03007995.2020.1783220"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2020.1783220","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}